Saudi Arabia Brain Cancer Therapeutics Market Report 2022 to 2030

Saudi Arabia Brain Cancer Therapeutics Market

$ 3999

Saudi Arabia Brain Cancer Therapeutics Market valued at $39 Mn in 2022, projected to reach $98 Mn by 2030 with a 12.1% CAGR. The market for brain cancer therapeutics is expected to be driven by the anticipated rise in the incidence of brain cancer, especially glioblastoma multiforme, which would raise the demand for therapeutics. The leading pharmaceutical companies presently operating in the industry are Roche, Merck, Novartis, Bristol Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, Teva Pharmaceutical Industries, Sanofi, and Ipsen.

ID: IN10SAPH439 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Dr. Medha Sansanwal

Buy Now

Saudi Arabia Brain Cancer Therapeutics Market Executive Summary

Saudi Arabia Brain Cancer Therapeutics Market valued at $39 Mn in 2022, projected to reach $98 Mn by 2030 with a 12.1% CAGR.

The abnormal multiplication of brain cells serves as an indicator of brain cancer, with these cells manifesting as either cancerous (malignant) or non-cancerous (benign). Despite the exact cause of brain cancer remaining elusive, identified risk factors encompass exposure to ionizing radiation and a family history of brain tumors. Symptoms commonly associated with a brain tumor involve headaches, gradual sensory decline, issues with balance, speech impediments, and hearing difficulties. The manifestation of these symptoms varies based on factors such as the tumor’s size, location, and growth rate. The treatment options for brain cancer are influenced by the type, location, and size of the tumor. Commonly employed treatments include radiosurgery, chemotherapy, radiotherapy, surgery, and the utilization of carmustine implants.

In Saudi Arabia, the prevalence of brain and central nervous system (CNS) cancer stands at 1,876 cases. Notably, the prevalence of brain tumors in the country is the highest in the region following Iran, with Riyadh province recording the highest number of cases. The prevalence rates for CNS tumors, specifically meningioma and glioblastoma, account for 26.99% and 25.10%, respectively. It's noteworthy that, in comparison, the prevalence of brain cancer in Saudi Arabia is relatively low, representing only 2.0 to 3.2% of the reported cases. These statistics underscore the significance of regional variations and specific tumor types within the broader landscape of brain and CNS cancer prevalence in Saudi Arabia.

In September 2023, Novartis took a significant step by signing a memorandum of understanding with Sudair Pharma, marking a collaboration aimed at technology transfer for the production of innovative cancer drugs within Saudi Arabia. Patients in Saudi Arabia may have easier access to cutting-edge brain cancer treatment options because of this strategic alliance. The knowledge transfer component emphasizes the dedication to regional manufacturing, which helps to make innovative cancer treatments more accessible and reasonably priced.

Market Dynamics

Market Growth Drivers

Advancements in Medical Research and Technology: Ongoing advancements in medical research and technology contribute to the development of innovative and more effective brain cancer treatment drugs. The adoption of novel therapeutic approaches enhances the market's growth by providing better outcomes and options for patients.

Strategic Collaborations and Partnerships: Collaborations and partnerships between global pharmaceutical companies and local entities in Saudi Arabia, as exemplified by the memorandum of understanding signed by Novartis and Sudair Pharma, contribute to the growth of the market. Such collaborations often involve technology transfer, enabling local production and improved accessibility to advanced treatment options.

Growing Awareness and Early Detection: Increasing awareness of brain cancer and its symptoms, coupled with the implementation of early detection programs, can lead to earlier diagnoses. Early intervention often necessitates a broader range of treatment options, thereby fostering the growth of the market.

Market Restraints

High Treatment Costs: The high costs associated with advanced brain cancer treatment drugs may pose a significant barrier. Affordability challenges for certain patient populations, coupled with limitations in insurance coverage, can restrict the widespread adoption of expensive pharmaceutical options.

Regulatory Challenges: Stringent regulatory processes and delays in the approval of new drugs may impede the timely introduction of innovative brain cancer treatments to the market. Regulatory hurdles can slow down the availability of cutting-edge medications, affecting patient access.

Cultural and Societal Stigmas: Cultural and societal factors may influence healthcare-seeking behavior, with stigmas associated with cancer potentially leading to delayed diagnosis and treatment initiation. Overcoming these stigmas and promoting a proactive approach to healthcare may be a challenge.

Healthcare Policies and Regulatory Landscape

In Saudi Arabia, the oversight of treatment drugs is governed by key healthcare policies and regulatory bodies. The Saudi Food and Drug Authority (SFDA) serves as the primary regulatory entity, ensuring the safety and quality of pharmaceuticals. The Ministry of Health (MOH) collaborates with SFDA to set healthcare policies, and its Drug Sector manages pharmaceutical affairs, including drug registration and pricing. The National Committee for Drug Control (NCDC) coordinates drug control efforts, emphasizing rational drug use and safety. The National Pharmacovigilance Centre (NPC) monitors pharmaceutical safety, and the Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI) indirectly impacts drug administration through healthcare institution accreditation.

Competitive Landscape

Key Players

Roche
Merck
Novartis
Bristol Myers Squibb
Eli Lilly
Pfizer
AstraZeneca
Teva Pharmaceutical Industries
Sanofi
Ipsen

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Saudi Arabia Brain Cancer Therapeutics Market Segmentation

By Type

Gliomas
Meningiomas
Pituitary Adenomas
Vestibular Schwannomas
Neuroectodermal Tumours

By Treatment

Chemotherapy
Immunotherapy
Targeted Drug Therapy
Radiation Therapy
Others

By End-Users

Hospitals
Oncology Specialty Clinics
Oncology Treatment Centres
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.